688221.SHG Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A
- Market cap
- CNY 4.85B
- P/E
- -
- P/B
- 4.45x
- ROE
- 28.8%
- Dividend yield
- 0.17%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688221.SHG undervalued?
Graham numberThe Graham number of Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A fundamental analysis
No fundamental analysis for Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A yet.
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A
Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patients' health in China. It offers Aikening, an IV fusion inhibitor for dual therapy of HIV-1. The company's pipeline products include FB2004 indicated for HBV; FB7011 and FB7013 for IgA nephropathy; FB7012 to treat hyperuricemia and gout; FB7041 to treat tumors; FB7024 for the treatment of hyperlipidemia; FB7023 …
Full company profileFrontier Biopharmaceuticals (Nanjing) Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 20.9M | 46.6M | 40.5M | 84.7M | 114M | 129M | 123M | 627M |
| Gross Profit | -10.4M | 8.59M | -12.3M | 15.8M | 33.1M | 43.9M | 41.0M | 527M |
| Operating Income | -180M | -237M | -312M | -375M | -331M | -232M | -241M | 278M |
| EBITDA | -156M | -196M | -220M | -301M | -275M | -149M | -216M | 307M |
| Net Income | -192M | -231M | -260M | -357M | -329M | -201M | -268M | 298M |
| EPS | -0.71 | -0.64 | -0.72 | -0.95 | -0.88 | -0.54 | -0.72 | 0.80 |
| Balance Sheet | ||||||||
| Total Assets | 940M | 2.53B | 2.53B | 2.41B | 2.14B | 1.81B | 1.58B | 1.75B |
| Total Liabilities | 337M | 385M | 702M | 739M | 797M | 671M | 701M | 712M |
| Shareholders' Equity | 603M | 2.14B | 1.83B | 1.67B | 1.34B | 1.14B | 877M | 1.03B |
| Cash & Short-term Investments | 227M | 839M | 801M | 551M | 527M | 249M | 170M | 393M |
| Cash Flow | ||||||||
| Operating Cash Flow | 34.3M | -170M | -243M | -289M | -267M | -173M | -227M | - |
| Capital Expenditure | 160M | 186M | 327M | 140M | 129M | 18.6M | 29.9M | 6.65M |
| Free Cash Flow | -126M | -357M | -570M | -429M | -397M | -191M | -256M | 355M |
| Ratios | ||||||||
| ROE | -31.9% | -10.8% | -14.2% | -21.3% | -24.5% | -17.6% | -30.6% | 28.8% |
| ROA | -20.5% | -9.1% | -10.3% | -14.8% | -15.4% | -11.1% | -17.0% | 17.1% |
| Net Profit Margin | -922.6% | -494.9% | -642.1% | -421.0% | -287.9% | -155.5% | -217.2% | 47.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A dividends
- Dividend yield
- 0.17%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 8.19M | 0.02 | - |
| 2024 | CNY 14.9M | 0.04 | - |
| 2023 | CNY 14.5M | 0.04 | - |
| 2022 | CNY 15.1M | 0.04 | - |
| 2021 | CNY 5.54M | 0.02 | - |
| 2020 | CNY 1.36M | 0.00 | - |
| 2019 | CNY 850K | 0.00 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A
- Insiders 40.34%
- Institutions 9.05%
- Public & others 50.61%
- Shares outstanding 375M
- Free float 227M
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A company profile
- Company name
- Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A
- Ticker
- 688221.SHG
- ISIN
- CNE100005XF5
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 265
- Fiscal year end
- December
- Address
- Building E-2, Greenland Window, Nanjing, China, 211199
- Phone
- 86 25 6964 8375
- Website
- frontierbiotech.com
About Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A
Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patients' health in China. It offers Aikening, an IV fusion inhibitor for dual therapy of HIV-1. The company's pipeline products include FB2004 indicated for HBV; FB7011 and FB7013 for IgA nephropathy; FB7012 to treat hyperuricemia and gout; FB7041 to treat tumors; FB7024 for the treatment of hyperlipidemia; FB7023 to treat ASCVD; FB7033 for the treatment of MASH; FB4001 for osteoporosis; and FB3002 for pain management. Frontier Biotechnologies Inc. was founded in 2002 and is headquartered in Nanjing, China.
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A management
9- Dr. Dong Xie Ph.D.Founder, Chairman, President & Chief Scientific Officer · born 1966
- Mr. Qi ShaoSenior VP, COO & CFO · born 1980
- Dr. Rongjian Lu Ph.D.CTO & Director · born 1962
- Mr. Hangzhou LvSenior Vice President of Marketing & Sales · born 1970
- Dr. Changjin Wang Ph.D.MD, CBO & Director · born 1958
- Ms. Qianya GaoVP, Deputy GM & Secretary of the Board of Directors · born 1986
- Xin GuanAccounting Supervisor
- Michael HuC.M.O.
- Michael WangSenior Vice President & Head of Infectious Diseases Therapy Area